General Information of Drug (ID: DMZ0TGY)

Drug Name
CGS 21680 Drug Info
Synonyms
2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; Cgs 21680; CGS-21680; 120225-54-9; UNII-T5HB1E831H; T5HB1E831H; CHEMBL331372; CGS21680; 4-(2-((6-Amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl)amino)ethyl)benzenepropanoic acid; CHEBI:73283; CGS 21680 hydrochloride; Benzenepropanoic acid, 4-(2-((6-amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl)amino)ethyl)-; 2-[p-(2-Carboxyethyl)phenylethyl-Amino]-5'-N-Ethylcarboxamido Adenosine; [3H]CGS 21680
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3086599
ChEBI ID
CHEMBL331372
CAS Number
CAS 120225-54-9
TTD Drug ID
DMZ0TGY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [7]
Istradefylline DM20VSK Parkinson disease 8A00.0 Approved [8]
Regadenoson DM76VHG Radionuclide imaging N.A. Approved [9]
Tozadenant DMATC14 Parkinson disease 8A00.0 Phase 3 [10]
Binodenoson DMVHF8G Hypertension BA00-BA04 Phase 3 [11]
Apadenoson DMD8QTC Coronary artery disease BA80 Phase 3 [12]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [13]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [14]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [15]
BIIB014 DMH7RJ1 Parkinson disease 8A00.0 Phase 2 [16]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [17]
Vidarabine DM0N85H Hepatosplenic T-cell lymphoma Approved [17]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [18]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [13]
YT-146 DM3YVKQ Hypertension BA00-BA04 Phase 2 [19]
AB928 DMDOXMN Metastatic colorectal cancer 2B91 Phase 1/2 [20]
KF-17837 DMQ6DLZ Parkinson disease 8A00.0 Phase 1 [21]
Xanthine DMFBOQ7 Apnea MD11.0 Phase 1 [22]
CVT-6883 DMY84TW Asthma CA23 Phase 1 [23]
PBF-1129 DMOPGXM Non-small-cell lung cancer 2C25.Y Phase 1 [20]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [24]
Methotrexate DM2TEOL Anterior urethra cancer Approved [25]
Quercetin DM3NC4M Obesity 5B81 Approved [26]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [27]
Testosterone DM7HUNW Hot flushes GA30 Approved [28]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [29]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [30]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [31]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [32]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [34]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [35]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [36]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [37]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [38]
Sodium lauryl sulfate DMLJ634 Constipation DD91.1 Approved [39]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [33]
Bexarotene DMOBIKY Cutaneous T-cell lymphoma 2B01 Approved [40]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [41]
Prednisolone DMQ8FR2 Acute adrenal insufficiency Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [24]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [30]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [33]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [43]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [44]
Clozapine DMFC71L Schizophrenia 6A20 Approved [45]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [46]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [47]
PMID28870136-Compound-52 DMFDERP N. A. N. A. Patented [48]
⏷ Show the Full List of 9 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [49]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [50]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [51]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [52]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [54]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [55]
Testosterone DM7HUNW Hot flushes GA30 Approved [56]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [36]
Aldosterone DM9S2JW Hypertension BA00-BA04 Approved [57]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [58]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [59]
Leflunomide DMR8ONJ Arthritis FA20 Approved [60]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [29]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [30]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [61]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [62]
Prednisolone DMQ8FR2 Acute adrenal insufficiency Approved [42]
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [63]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Catenin beta-1 (CTNNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [64]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [65]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [66]
Quercetin DM3NC4M Obesity 5B81 Approved [67]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [68]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [69]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [70]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [71]
Testosterone DM7HUNW Hot flushes GA30 Approved [72]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [73]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A2a receptor (ADORA2A) TTM2AOE AA2AR_HUMAN Agonist [2]
Adenosine A2b receptor (ADORA2B) TTNE7KG AA2BR_HUMAN Agonist [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Basic helix-loop-helix ARNT-like protein 1 (BMAL1) OTMI12L2 BMAL1_HUMAN Gene/Protein Processing [4]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Protein Interaction/Cellular Processes [5]
Circadian locomoter output cycles protein kaput (CLOCK) OTNEOJY7 CLOCK_HUMAN Gene/Protein Processing [4]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Gene/Protein Processing [5]
Nuclear receptor subfamily 1 group D member 1 (NR1D1) OTJ38PTB NR1D1_HUMAN Gene/Protein Processing [4]
Period circadian protein homolog 2 (PER2) OTU2B1DJ PER2_HUMAN Gene/Protein Processing [4]
Vascular endothelial growth factor A, long form OTIM9MZ3 VEGFA_HUMAN Protein Interaction/Cellular Processes [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 424).
2 Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol. 2002 Mar 8;438(3):183-8.
3 [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther. 1989 Dec;251(3):888-93.
4 Adenosine A2A receptor and TNF- regulate the circadian machinery of the human monocytic THP-1 cells. Inflammation. 2013 Feb;36(1):152-62. doi: 10.1007/s10753-012-9530-x.
5 Adenosine A(2A) receptor promotes collagen type III synthesis via -catenin activation in human dermal fibroblasts. Br J Pharmacol. 2016 Dec;173(23):3279-3291. doi: 10.1111/bph.13615. Epub 2016 Oct 4.
6 Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem Biophys Res Commun. 2010 Feb 12;392(3):351-6. doi: 10.1016/j.bbrc.2010.01.023. Epub 2010 Jan 11.
7 Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
10 Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
11 Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
13 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
14 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
15 Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
16 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
18 Clinical pipeline report, company report or official report of Klus Pharma
19 Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
20 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
21 Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
22 Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
23 GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
24 Tea polyphenols ameliorates neural redox imbalance and mitochondrial dysfunction via mechanisms linking the key circadian regular Bmal1. Food Chem Toxicol. 2017 Dec;110:189-199. doi: 10.1016/j.fct.2017.10.031. Epub 2017 Oct 20.
25 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
26 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
27 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
28 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
29 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
30 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
31 Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One. 2011;6(9):e25612. doi: 10.1371/journal.pone.0025612. Epub 2011 Sep 28.
32 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
33 Glucocorticoids affect 24 h clock genes expression in human adipose tissue explant cultures. PLoS One. 2012;7(12):e50435. doi: 10.1371/journal.pone.0050435. Epub 2012 Dec 10.
34 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
35 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
36 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
37 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
38 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
39 CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
40 Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
41 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
42 Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Mol Endocrinol. 2006 Mar;20(3):573-83. doi: 10.1210/me.2005-0165. Epub 2005 Nov 3.
43 Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 2011 Feb 2;30(3):510-23. doi: 10.1038/emboj.2010.333. Epub 2010 Dec 14.
44 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
45 Genetic dissection of drug effects in clinical practice: CLOCK gene and clozapine-induced diurnal sleepiness. Neurosci Lett. 2004 Sep 2;367(2):152-5. doi: 10.1016/j.neulet.2004.05.084.
46 Gene expression changes associated with altered growth and differentiation in benzo[a]pyrene or arsenic exposed normal human epidermal keratinocytes. J Appl Toxicol. 2008 May;28(4):491-508.
47 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
48 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
49 Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
50 SNHG3 cooperates with ELAVL2 to modulate cell apoptosis and extracellular matrix accumulation by stabilizing SNAI2 in human trabecular meshwork cells under oxidative stress. Environ Toxicol. 2021 Jun;36(6):1070-1079. doi: 10.1002/tox.23106. Epub 2021 Feb 1.
51 Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
52 A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One. 2006 Dec 20;1(1):e97. doi: 10.1371/journal.pone.0000097.
53 Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br J Dermatol. 2003 Mar;148(3):544-52. doi: 10.1046/j.1365-2133.2003.05174.x.
54 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
55 Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
56 Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56. doi: 10.1007/s13539-011-0021-y. Epub 2011 Feb 26.
57 Modelling cardiac fibrosis using three-dimensional cardiac microtissues derived from human embryonic stem cells. J Biol Eng. 2019 Feb 13;13:15. doi: 10.1186/s13036-019-0139-6. eCollection 2019.
58 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
59 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
60 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
61 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
62 Functional characterization of an orphan nuclear receptor, Rev-ErbAalpha, in chondrocytes and its potential role in osteoarthritis. Arthritis Rheum. 2006 Nov;54(11):3513-22. doi: 10.1002/art.22170.
63 System analysis of cross-talk between nuclear receptors reveals an opposite regulation of the cell cycle by LXR and FXR in human HepaRG liver cells. PLoS One. 2019 Aug 22;14(8):e0220894. doi: 10.1371/journal.pone.0220894. eCollection 2019.
64 Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
65 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
66 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
67 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
68 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
69 Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
70 Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
71 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
72 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
73 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.